Results 21 to 30 of about 20,100 (304)

Long‐term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real‐world setting

European Journal of Haematology, 2023
Describe the real‐world clinical profile of eculizumab‐treated patients by characterizing their short‐ and long‐term clinical and laboratory outcomes.
Katharina Versmold, F. Alashkar, Carina Raiser, R. Ofori-Asenso, T. Xu, Yutong Liu, P. Katz, A. Shang, A. Röth   +8 more
semanticscholar   +1 more source

Eculizumab‐related drug reaction in a patient with neuromyelitis optica

Clinical Case Reports, 2023
Eculizumab is approved for treatment of antibody positive neuromyelitis optica, myasthenia gravis, and hematologic disorders like paroxysmal nocturnal hemoglobinuria. Drug rash has not yet been reported as a side effect of eculizumab. We report a case of
Rishi Sharma, Moises Romo, Flavia Nelson
doaj   +1 more source

Serious Bacterial Infections Associated with Eculizumab: A Pharmacovigilance Study

Internal medicine, 2023
Objective Molecular-targeted agents, including eculizumab and rituximab, are considered treatment options for refractory myasthenia gravis (MG), but bacterial infections can occur as serious adverse events when using these agents.
Shohei Okusa, T. Takizawa, Shungo Imai, M. Oyama, Kei Ishizuchi, Jin Nakahara, Satoko Hori, Shigeaki Suzuki   +7 more
semanticscholar   +1 more source

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab [PDF]

Clinical Pharmacokinetics, 2019
Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic
Lambertus P. van den Heuvel, Lambertus P. van den Heuvel, Lambertus P. van den Heuvel, Dirk Jan A.R. Moes, Saskia Langemeijer, Elena B. Volokhina, Elena B. Volokhina, Nicole C. A. J. van de Kar, Kioa L. Wijnsma, Saskia E M Schols, Rob ter Heine, Jack F.M. Wetzels, Roger J. M. Brüggemann   +12 more
openaire   +5 more sources

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient

Frontiers in Immunology, 2021
BackgroundWith the introduction of eculizumab, a C5-inhibitor, morbidity and mortality improved significantly for patients with atypical hemolytic uremic syndrome (aHUS).
Romy N. Bouwmeester, Mendy Ter Avest, Kioa L. Wijnsma, Caroline Duineveld, Rob ter Heine, Elena B. Volokhina, Lambertus P. W. J. Van Den Heuvel, Jack F. M. Wetzels, Nicole C. A. J. van de Kar   +8 more
doaj   +1 more source

Ischemia and reperfusion injury in kidney transplantation : relevant mechanisms in injury and repair [PDF]

, 2020
Ischemia and reperfusion injury (IRI) is a complex pathophysiological phenomenon, inevitable in kidney transplantation and one of the most important mechanisms for non- or delayed function immediately after transplantation.
Berger, Stefan P., Leuvenink, Henri G. D., Nieuwenhuijs-Moeke, Gertrude J., Pischke, Soren E., Ploeg, Rutger J., Pol, Robert A., Sanders, Jan Stephan F., Struys, Michel   +7 more
core   +2 more sources

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder

Frontiers in Neurology, 2021
Objective: To investigate the pharmacokinetics and pharmacodynamics of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).Methods ...
Pratap Singh, Xiang Gao, Huub Jan Kleijn, Francesco Bellanti, Ryan Pelto   +4 more
doaj   +1 more source

The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey

Annals of Hematology, 2022
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening disease with symptoms of hemolysis and thrombosis. Current therapies for this complement-mediated disease rely predominantly on inhibition of the C5 complement protein.
D. Dingli, J. E. Matos, K. Lehrhaupt, S. Krishnan, M. Yeh, J. Fishman, S. Sarda, S. Baver   +7 more
semanticscholar   +1 more source

Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.

PLoS ONE, 2020
IntroductionEculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk.
Catherine H Bozio, Cheryl Isenhour, Lucy A McNamara   +2 more
doaj   +1 more source

Aplicaciones terapéuticas del eculizumab

Universidad y Salud, 2022
Introducción: El eculizumab es un anticuerpo monoclonal de tipo IgG diseñado para el tratamiento de la hemoglobinuria paroxística nocturna (HPN), en el que su diana farmacológica forma parte del sistema del complemento. Su mecanismo de acción ha permitido implementarlo en el tratamiento de enfermedades huérfanas, como el síndrome urémico hemolítico ...
Luz Chacón-Jiménez, Johanna Rodríguez-Jiménez, Susana Ruiz-Jiménez, Natalia Campos-González   +3 more
openaire   +5 more sources